Health
FDA Extends Decision Deadline for AstraZeneca Breast Cancer Pill
The FDA has extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug. The outcome is expected to impact future clinical trials and regulatory approval.
Coverage timeline — 1 article
STAT News
The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug
2026-05-27 13:33 UTC